Advertisement

Digestive Diseases and Sciences

, Volume 58, Issue 11, pp 3112–3116 | Cite as

Gastrointestinal Stromal Tumor: An Unusual Cause of Gastrointestinal Bleeding

  • Robert J. Wong
  • Teri A. Longacre
  • George Poultsides
  • Walter Park
  • Michael E. Rothenberg
Stanford Multidisciplinary Seminars

Keywords

Imatinib Sunitinib Papillary Thyroid Carcinoma Gastrointestinal Stromal Tumor Nilotinib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005;100:162–168.PubMedCrossRefGoogle Scholar
  2. 2.
    Surveillance, Epidemiology, and End Results (SEER) Program. Research data (1973–2009). National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission. www.seer.cancer.gov.
  3. 3.
    Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70–83.PubMedCrossRefGoogle Scholar
  4. 4.
    Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT). Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;153:1259–1269.Google Scholar
  5. 5.
    Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580.PubMedCrossRefGoogle Scholar
  6. 6.
    Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol. 2002;10:81–89.PubMedCrossRefGoogle Scholar
  7. 7.
    Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61:8118–8121.PubMedGoogle Scholar
  8. 8.
    Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710.PubMedCrossRefGoogle Scholar
  9. 9.
    Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003;125:660–667.PubMedCrossRefGoogle Scholar
  10. 10.
    Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23:5357–5364.PubMedCrossRefGoogle Scholar
  11. 11.
    Dematteo RP, Ballman KV, Antonescu CR, et al. American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumor: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–1104.PubMedCrossRefGoogle Scholar
  12. 12.
    Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265–1272.PubMedCrossRefGoogle Scholar
  13. 13.
    Demetri GD, von Mehren M, Antonescu CR, et al. NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cancer Netw. 2010;8:S1–S41.Google Scholar
  14. 14.
    Demetri GD, Reichardt P, Kang YK, et al. GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302.PubMedCrossRefGoogle Scholar
  15. 15.
    Edris B, Willingham SB, Weiskopf K, et al. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proc Natl Acad Sci USA. 2013;110:3501–3506 Google Scholar
  16. 16.
    Watson RR, Binmoeller KF, Hamerski CM, et al. Yield and performance characteristics of endoscopic ultrasound-guided fine needle aspiration for diagnosing upper GI tract stromal tumors. Dig Dis Sci. 2011;56:1757–1762.PubMedCrossRefGoogle Scholar
  17. 17.
    Privette A, McCahill L, Borrazzo E, Single RM, Zubarik R. Laparoscopic approaches to resection of suspected gastric gastrointestinal stromal tumors based on tumor location. Surg Endosc. 2008;22:487–494.PubMedCrossRefGoogle Scholar
  18. 18.
    Malek R, McCarthy-Keith D, Levens ED, et al. A gastrointestinal stromal tumor in a patient with multiple endocrin neoplasia type 2A and metastatic medullary thyroid cancer to the ovaries. Endocr Pract. 2008;14:898–901.PubMedCrossRefGoogle Scholar
  19. 19.
    Basu S, Nair N, Mohandas KM. FDG-avid thyroid incidentaloma in advanced gastrointestinal stromal tumor: metachronous dual primaries. Indian J Gastroenterol. 2007;26:146–147.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Robert J. Wong
    • 1
    • 2
  • Teri A. Longacre
    • 3
  • George Poultsides
    • 4
  • Walter Park
    • 1
    • 2
  • Michael E. Rothenberg
    • 1
    • 2
  1. 1.Department of MedicineStanford University Medical CenterStanfordUSA
  2. 2.Division of Gastroenterology and HepatologyStanford University Medical CenterStanfordUSA
  3. 3.Department of PathologyStanford University Medical CenterStanfordUSA
  4. 4.Department of SurgeryStanford University Medical CenterStanfordUSA

Personalised recommendations